Re-mark
Hepatitis B and C Virus: Present Treatment, R&D, Upcoming Treatment As per the Centers for Disease Control and Prevention estimates, approximately 850,000–2.2 million people were living with chronic Hepatitis B in the United States in 2016, while about 2.0–2.5 million US residents were living with chronic Hepatitis C. Although no curative therapy is available in the market, therapies offer a way to inhibit the virus. However, the new antiviral therapies in clinical trials, several novel therapies are expected to control the HBV replication at an early stage. In the case of HCV, the hepatitis C therapeutics market is set to experience a steady decline owing to declining patient populations and unusually high DAA treatment rates.
You may like
Matte Visiting Cards
#MatteVisitingCards, #MatteFinish, #ElegantBusinessCards, #SmoothTouch, #PremiumQuality, #CustomMatteCards, #ModernDesign
Glossy Business Cards
#GlossyBusinessCards, #HighGlossFinish, #ShinyBusinessCards, #LuxuryVisitingCards, #PremiumPrinting, #ProfessionalDesign, #VibrantColors
Eco-Friendly Business Card
#EcoFriendlyBusinessCards, #SustainableDesign, #RecycledPaperCards, #GreenPrinting, #EcoBranding, #BiodegradableCards, #EnvironmentFriendly